Zenas BioPharma Email Formats
Biotechnology Research • 
Waltham, Massachusetts, United States • 101-200 Employees
Zenas BioPharma Email Formats
Zenas BioPharma uses 5 email formats. The most common is {first initial}.{last name} (e.g., j.doe@zenasbio.com), used 88.1% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@zenasbio.com | 88.1% |
{first name}.{last name} | john.doe@zenasbio.com | 8.3% |
{first initial}.{second initial} | j.o@zenasbio.com | 1.2% |
{first initial} | j@zenasbio.com | 1.2% |
{first name}{last name} | johndoe@zenasbio.com | 1.2% |
Key Contacts at Zenas BioPharma
Jose Silveiras
Executive Director, Site Relationship & Clinical Monitoring
Nuran Chaban Navarro
European Associate Director Medical Science Liaison
Boxu Yan
Executive Director
Caroline Duque
Director, Global Quality Assurance, Clinical Development & Operations
Dania Kanj Pharmd
Director, Scientific Communications
Juno Kim
Associate Director, Clinical Operations
Shaheen Nageeb
Medical Science Liaison, Associate Director
Jessica Schutt
Director, Medical Writing
Kathleen Casey
Director, Hr Operations
Cathy Maxwell
Senior Director, Medical Engagement And Patient Advocacy
Company overview
| Headquarters | 1000 Winter St, Suite 1200, Waltham, MA 02451, US |
| Phone number | +18572712954 |
| Website | |
| NAICS | 541714 |
| Keywords | Autoimmune Diseases And Immunology |
| Employees | 101-200 |
| Socials |
About Zenas BioPharma
Zenas BioPharma (Nasdaq: ZBIO) is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative immunology-based therapies for patients in need. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas’ lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab’s mechanism of action and chronic dosing regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease.
Employees by Management Level
Total employees: 101-200
Seniority
Employees
Employees by Department
Zenas BioPharma has 67 employees across 12 departments.
Departments
Number of employees
Funding Data
Explore Zenas BioPharma's funding history, including investment rounds, total capital raised, and key backers.
Zenas BioPharma Tech Stack
Discover the technologies and tools that power Zenas BioPharma's digital infrastructure, from frameworks to analytics platforms.
Security
Form builders
JavaScript libraries
JavaScript libraries
CDN
Font scripts
JavaScript libraries
Miscellaneous
Programming languages
Blogs
Hosting
Analytics
United Arab Emirates
Finland
United KingdomFrequently asked questions
4.8
40,000 users
